This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Feb 28;346(9):705-7.

doi: 10.1056/NEJM200202283460912.

Angiotensin-receptor blockers, type 2 diabetes, and renoprotection

Robert P Blankfield

PMID: 11870250
DOI: 10.1056/NEJM200202283460912

Comment

Angiotensin-receptor blockers, type 2 diabetes, and renoprotection

Robert P Blankfield. N Engl J Med. 2002.

. 2002 Feb 28;346(9):705-7.

doi: 10.1056/NEJM200202283460912.

Author

Robert P Blankfield

PMID: 11870250
DOI: 10.1056/NEJM200202283460912

No abstract available

PubMed Disclaimer

Comment on

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Lewis EJ, et al. N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303. N Engl J Med. 2001. PMID: 11565517 Clinical Trial.
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Brenner BM, et al. N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161. N Engl J Med. 2001. PMID: 11565518 Clinical Trial.
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. Parving HH, et al. N Engl J Med. 2001 Sep 20;345(12):870-8. doi: 10.1056/NEJMoa011489. N Engl J Med. 2001. PMID: 11565519 Clinical Trial.

Similar articles

Prevention of end-stage renal disease due to type 2 diabetes.
Hostetter TH. Hostetter TH. N Engl J Med. 2001 Sep 20;345(12):910-2. doi: 10.1056/NEJM200109203451209. N Engl J Med. 2001. PMID: 11565525 No abstract available.
Diabetic nephropathy.
Goto A. Goto A. N Engl J Med. 2002 Sep 19;347(12):947-8; author reply 947-8. doi: 10.1056/NEJM200209193471218. N Engl J Med. 2002. PMID: 12239270 No abstract available.
Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Crook ED, Preddie DC. Crook ED, et al. Ethn Dis. 2002 Fall;12(4):S3-49-52. Ethn Dis. 2002. PMID: 12477155
The expanding role of angiotensin receptor blockers in the management of the elderly hypertensive.
McInnes GT. McInnes GT. Curr Med Res Opin. 2003;19(5):452-5. doi: 10.1185/030079903125001992. Curr Med Res Opin. 2003. PMID: 13678487 Review.
Toward better renoprotection: lessons from angiotensin receptor blockers.
Miyata T, Takizawa S. Miyata T, et al. Hemodial Int. 2007 Apr;11(2):164-8. doi: 10.1111/j.1542-4758.2007.00164.x. Hemodial Int. 2007. PMID: 17403166 Review.

See all similar articles

Cited by

Enalapril reduces germ cell toxicity in streptozotocin-induced diabetic rat: investigation on possible mechanisms.
Kushwaha S, Jena GB. Kushwaha S, et al. Naunyn Schmiedebergs Arch Pharmacol. 2012 Feb;385(2):111-24. doi: 10.1007/s00210-011-0707-x. Epub 2011 Nov 10. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22071577

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information